Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 Alone or With Decitabine in Relapsed/Refractory Hodgkin Lymphoma
NCT03250962Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2017
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, camrelizumab in Hodgkin lymphoma (HL), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
decitabinecamrelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03250962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250962.